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Intra-arterial (IA) chemotherapy for curative treatment of head and neck cancer experienced a revival in the last decade. Mainly, it
was used in concurrent combination with radiation in organ-preserving settings. The modern method of transfemoral approach for
catheterisation, superselective perfusion of the tumour-feeding vessel, and high-dose (150mgm
 2) administration of cisplatin with
parallel systemic neutralisation with sodium thiosulphate (9gm
 2) made preoperative usage feasible. The present paper presents the
results of a pilot study on a population of 52 patients with resectable stage 1–4 carcinomas of the oral cavity and the oropharynx,
who were treated with one cycle of preoperative IA chemotherapy executed as mentioned above and radical surgery. There have
been no interventional complications of IA chemotherapy, and acute side effects have been low. One tracheotomy had to be carried
out due to swelling. The overall clinical local response has been 69%. There was no interference with surgery, which was carried out
3–4 weeks later. Pathological complete remission was assessed in 25%. The mean observation time was 3 years. A 3-year overall and
disease-free survival was 82 and 69%, respectively, and at 5 years 77 and 59%, respectively. Survival results were compared to a
treatment-dependent prognosis index for the same population. As a conclusion, it can be stated that IA high-dose chemotherapy
with cisplatin and systemic neutralisation in a neoadjuvant setting should be considered a feasible, safe, and effective treatment
modality for resectable oral and oropharyngeal cancer. The low toxicity of this local chemotherapy recommends usage especially in
stage 1–2 patients. The potential of survival benefit as indicated by the comparison to the prognosis index should be controlled in a
randomised study.
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Intra-arterial (IA) local chemotherapy for curative treatment of
head and neck cancer experienced a revival in the last decade.
Mainly, it was used in concurrent combination with radiation
(Robbins et al, 1994; Shibuya et al, 1994; von Scheel et al, 1996;
Fuwa et al, 2000; Furutani et al, 2002; Yamashita et al, 2002;
Kitagawa et al, 2003) or alone (Nakasato et al, 2000). The drugs
used mainly have been cisplatin or carboplatin. Administration
was either continuously over a temporal retrograde approach
(Fuwa et al, 2000; Nakasato et al, 2000; Furutani et al, 2002) or by
repeated bolus infusions over a transfemoral anterograde
approach (Robbins et al, 1994). The temporal approach had the
general disadvantage of not being selective or superselective. The
main aim of these trials was organ preservation in patients with
advanced cancer, and the reported overall survival rate in the
studies with acceptable minimal observation time (median 3 years)
were 39% (von Scheel et al, 1996), 64% (local control rate; Fuwa
et al, 2000), and 58.9% (Furutani et al, 2002). The largest popu-
lation consisting of 213 patients was the one Robbins et al (2000b)
reported, and overall and cancer-related 5-year survival of these
patients with stages 3–4 disease was 38.8 and 53.6%, respectively.
Truly neoadjuvant usage (before definitive treatment by surgery
or radiation), with an exclusive transfemoral approach and
superselective perfusion, has been rare (Korogi et al, 1995; Hirai
et al, 1999; Benazzo et al, 2000; Damascelli et al, 2003). By far, the
largest population (213 patients) in this group was reported by
Kova ´cs et al (1999) and Kova ´cs (2003a); the other investigators
having reported between 13 and 23 patients. Performing a
modification of the method adopted by Robbins et al (1994,
2000b) for the head and neck (IA high-dose cisplatin plus systemic
antagonisation with sodium thiosulphate), Kova ´cs and co-workers
could clinically and pharmacologically demonstrate a very low rate
of acute side effects in the neoadjuvant setting (Kova ´cs et al, 2002;
Kova ´cs, 2003a,b; Tegeder et al, 2003). In the period between 1996
and today (September 2003), over 350 patients with primary and
recurrent malignancies of the head and neck have been treated
with IA high-dose cisplatin in the author’s institution.
Nearly all hitherto reports concentrated on interventional safety
and tumour response. The proceedings of an international meeting
on IA chemotherapy in head and neck cancer at Hanover in 1997
demonstrated the problems of many studies concerning patient
survival. For example, Japanese results could not easily be
compared to European ones due to a high number of maxillary
sinus carcinomas, regular temporal retrograde approach with
continuous infusion, various combinations with radiation, which
were frequently unplanned, and rarely used anticancer drugs like
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lpeplomycin (Hibi et al, 1999; Inuyama, 1999). Molinari, who had
the hitherto greatest European experience (168 patients) with
neoadjuvant IA chemotherapy, complained about the difficulties of
providing homogeneous populations (Molinari et al, 1999).
Diverse use of antineoplastic agents and mingling with post-
operative surgery considerably reduced the number of patients in
whom survival could be attributed to the additional effect of IA
chemotherapy.
The aim of the presented paper is to discuss long-term survival
of a population of 52 patients with resectable oral and
oropharyngeal cancer solely treated with neoadjuvant IA high-
dose chemotherapy and surgery with curative intention, and to
show the feasibility, safety, and efficacy of that neoadjuvant
treatment modality.
MATERIAL AND METHODS
The demographic and pretherapeutic tumour-related data of the
patients are summarised in Tables 1 and 2. All tumours were
histologically confirmed and previously untreated squamous cell
carcinomas.
All patients of this study were considered fit for anaesthesia, and
primaries and neck disease were judged to be resectable.
All oral cancer patients of our institution have been treated with
a multimodality regimen consisting of neoadjuvant IA chemother-
apy, surgery, and adjuvant radiation with concurrent systemic
chemotherapy (Kova ´cs, 2003b). Patients with T1 primaries were
not treated with adjuvant radiotherapy. The omission of radio-
therapy in the stage 2–4 patients reported in this paper was not the
result of iatrogenic selection but of patient refusal (n¼25), and
objective contraindications for radiotherapy, like psychiatric
disease (claustrophobia, organic brain syndrome, alcoholism with
delirium; n¼4), prolongated wound healing (n¼7), dyspnoea
(n¼1), and earlier radiotherapy of the same area (n¼4). The four
patients with prior radiotherapy suffered from earlier primaries
(each one from a non-Hodgkin lymphoma and oropharyngeal
cancer, and twice from a laryngeal cancer), all more than 5 years
before this study and without relapse. The male/female distribu-
tion showed less male patients than usual because men generally
were more sympathetic to postoperative radiation. Finally, a
population of 52 patients could be examined who were treated
solely with neoadjuvant IA high-dose chemotherapy and surgery.
Approval of the local ethical committee was given, and patients
signed informed consent.
The routine pretherapeutic staging took place using palpation,
ultrasound, CT, and MRT for diagnostics of neck lymph nodes as
well as PET for diagnostics of secondary tumours, neck lymph
node affection, and distant metastases.
Every patient was treated initially with one cycle of adjuvant IA
high-dose chemotherapy.
In the morning of the intervention, the patients received 74mg
dolasetron and 75mg prednisolone intravenously (i.v.) Afterwards,
1.5l of a full electrolyte solution including 20mval potassium
chloride were infused i.v. over a period of 2h. Then the right
femoral artery was catheterised using a four-french catheter
containing a coaxial microcatheter. After superselective visualisa-
tion of the tumour-feeding vessel using fluoroscopy and a contrast
medium, 150mgm
 2 cisplatin (medac GmbH, Hamburg, Ger-
many; maximal absolute dose 300mg) dissolved in 500ml 0.9%
saline solution was infused at 2mls
 1 with controlled pressure.
For analgesia, 0.1–0.3mg fentanyl was delivered i.v. (and on
occasions of tooth aching 5–15mg mepivacain) into the perfused
artery. After 10s, an i.v. infusion of 9gm
 2 sodium thiosulphate
was administered in parallel to the perfusion. After chemoperfu-
sion was completed, no more sodium thiosulphate was given.
Starting in May 2000, tumour sites in the floor of mouth and the
mobile tongue have been treated with an aqueous crystal
suspension of cisplatin (5mg in 1ml); the absolute dose of
cisplatin has been the same (Kova ´cs et al, 2002). After the
treatment, 1l of full electrolyte solution containing 20mval
potassium chloride was infused again i.v. during a period of 5h.
The next day, the patients were hyperhydrated with 3l of a two-
third electrolyte solution, received thrombosis prophylaxis with
heparin s.c., and dolasetron i.v. if nausea was present. Routine
laboratory checks were made on alternate days. Ward stay lasted
between 4 and 6 days for most patients. The side effects of the
cycles according to WHO (Miller et al, 1981) were noted.
Remission was assessed clinically (by inspection and palpation)
and by CT 3 weeks after the first cycle. The remission was graded
as: CR¼complete remission, a complete disappearance of local
tumour mass; PR¼partial remission, a reduction of local tumour
mass of more than 50%; SD¼stable disease, a reduction of local
tumour mass of less than 50% or identical local tumour mass;
PD¼progressive disease, continued growth of the tumour.
The second stage was the operation. As a therapeutically
effective ‘downstaging’ of the tumour was considered pointless,
all resections were performed according to the pretherapeutic
tumour extension plus healthy margins, as documented by
pretherapeutic photography and CT.
Treatment of the neck was carried out according to the
guidelines of the DO ¨SAK (Bier, 1982) with two important
Table 1 Patient characteristics
Characteristic n (%)
No. patients 52
Gender
Male 28 (54)
Female 24 (46)
Median age (years) (range) 66 (38–89)
ECOG performance status
0 26 (50)
1 23 (44)
2 2 (4)
3 1 (2)
Primary tumour site
Floor of the mouth 17 (33)
Tongue 15 (29)
Mandibular alveolar process 7 (13)
Oral cheek mucosa 2 (4)
Retromolar trigone 3 (6)
Maxilla 1 (2)
Oropharynx 7(13)
Clinical stage (UICC)
1 11 (21)
2 17 (33)
3 6 (11)
4 18 (35)
ECOG = Eastern Cooperative Oncology Group. Stage according to Union
Internationale Contre le Cancer (UICC; Sobin and Wittekind, 1997).
Table 2 Distribution of cT and cN stages at baseline
cN0 cN1 cN2a cN2b cN2c Total
cT1 11 0 0 0 0 11 (21%)
cT2 17 3 0 0 2 22 (42%)
cT3 3 0 0 0 1 4 (8%)
cT4 5 4 0 4 2 15 (29%)
Total 36 7 0 4 5 52 (100%)
CT=clinical tumor classification. CN=clinical nodal classification.
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lmodifications: if pretherapeutic staging including PET resulted in
the diagnosis of a clinically negative neck (cN0), only a suprahyoid
neck dissection (SHND, a selective neck dissection that includes
neck levels I and IIa) was carried out homolaterally, irrespective of
the localisation and size of the primary tumour. In case of a
positive pretherapeutic finding on whichever side of the neck, a
Type III modified radical neck dissection (MRND III) was carried
out. If the histologic examination of the neck specimen revealed
positive nodes despite a pretherapeutic cN0 classification, an
MRND of levels IIb, III, IV, and V was performed as early as
possible. (The classifications of neck levels and types of operations
follow the proposal of the American Head and Neck society
(Robbins et al, 2000a).) Beginning in March 2000, sentinel node
biopsy was executed instead of SHND in case of cN0 (Kova ´cs et al,
2001). In case of positive sentinel nodes, an MRND was performed
1 week after SNB.
Survival of this population could be compared to a prognosis
index. The treatment-dependent prognosis index (TPI) (Platz et al,
1985; Platz et al, 1992; Howaldt, 1999) was assessed for the
population as demonstrated in Table 1. Treatment-dependent
prognosis index combines data on tumour size (40mm4x4
40mm), depth of tumour infiltration (5mm4x45mm), evidence
of fixed lymph nodes (yes/no), presence of distant metastases (yes/
no), and age (50450–70470 years) based on two observational
(one retrospective and one prospective) studies of the DO ¨SAK
(Deutsch-O ¨sterreichisch-Schweizerischer Arbeitskreis fu ¨r Tumo-
ren im Kiefer-und Gesichtsbereich, German–Austrian–Swiss
Cooperative Group on tumours of the maxillofacial region)
comprising a total of 2500 patients. In all, 48 (2 2 2 2 3)
combinations of these data are possible (¼TPI groups 1–48). In
every TPI group, patients are divided into two prognostic
subgroups, according to the kind and success of treatment: those
operated on radically and without/with clinical evidence of disease
after completion of therapy, and those treated either surgically but
not radically or with primary radiotherapy, and without/with
clinical evidence of disease after completion of therapy. Each
subgroup has its own prognostic prediction (expected survival at
five points¼years 1, 2, 3, 4, and 5) according to the results of the
above-mentioned observational studies. For instance, the TPI 2 has
a 5-year survival expectancy of 72% and the TPI 38 one of 46% in
case of radical surgery leaving no clinical evidence of disease.
Calculation of the index was carried out using the Cox regression.
This enabled a control for the present population. The prognostic
indices for patients operated on radically and without clinical
evidence of disease could be used for the patients of the present
study and resulted in expected survival rates as shown in Table 3.
Cumulative survival and disease-free survival for all patients
were calculated by the Kaplan–Meier method (Kaplan and Meier,
1958). The mean survival time including its 95% confidence was
estimated (SPSS Statistical Algorithms, 1991), and the cumulative
percentage of surviving subjects was calculated for 1, 2, 3, 4, and 5
years including 95% confidence intervals. The number of subjects
at risk and cumulative events over time were calculated and are
below the time axis of each Kaplan–Meier curve.
The difference of the TPI estimator with respect to the
confidence range of the calculated survival was evaluated. The
TPI estimator is predicted by a Cox regression equation based on
the above-mentioned studies of the DO ¨SAK, while the estimators
of the presented sample are based on the Kaplan–Meier method.
Therefore, a classical test of difference (e.g. log rank) between the
observed sample and population data could not be carried out. An
indicator for any difference between the resulting curves for
survival and expected survival could be that the TPI estimator is
outside the confidence range for survival calculated in this sample.
RESULTS
Intra-arterial high-dose chemotherapy was executed in every
patient, once in 48 patients and twice in four patients (¼56
interventions). In these cases of PR after the first cycle, assessed
visually and by CT, the cycle was repeated, and these four patients
(8%) have not been excluded because the study goals of feasibility,
safety, and efficacy were not affected, and survival analysis was
only potentially affected.
There have been no interventional complications. One adipose
patient with a T2 cancer of the anterior floor of mouth developed a
submental swelling with dyspnoea; a tracheotomy was executed 1
day after the intervention. The patient could be decannulated 3
days later without further complications. The acute side effects of
IA chemotherapy are noted in Table 4. In sum, IA chemotherapy
had few and low-grade acute side effects.
Remissions as assessed clinically after the first cycle were: CR 20
patients (38%), PR 16 patients (31%), and SD 16 patients (31%).
This indicates a clinical response rate (CRþPR) of 69%.
Surgery was carried out according to the generally accepted
rules of radicality and reconstruction without unusual complica-
tions. Especially, microsurgery was not disturbed by alterations of
the vessels used for chemoperfusion. The treatment of the neck is
listed in Table 5. Four patients already had neck surgery due to
earlier primaries at different sites. In sum, neck treatment had to
be considered as conservative with the aim of preservation of
functions. Histopathological examination of the primary specimen
confirmed the ‘downstaging’ of the primaries, including a rate of
25% pathological CRs (Table 6). Pathological stages were: stage 0/
11 patients, 1/19, 2/5, 3/6, and 4/11. Although local radicality was
not affected by ‘downstaging’, surgery was facilitated by higher
topographical clarity and a higher consistency of the tumours
making them better palpable.
In all, 10 patients suffered from relapse: seven from local relapse
and four from regional relapse in the neck. Five of these
recurrences could be treated by salvage surgery.
Table 3 Distribution of TPI with prognosis for patients operated on
radically and without clinical evidence of disease
TPI
Expected 3-
year survival
(%)
Expected 5-
year survival
(%)
Number of
patients
18 3 7 9 3
27 7 7 2 7
37 0 6 4 4
13 72 66 4
14 64 57 16
15 54 47 11
21 33 25 1
38 54 46 2
39 43 35 3
44 33 25 1
TPI¼treatment-dependent prognosis index.
Table 4 Acute side effects of IA chemotherapy
Toxicity Grade I Grade II
Nausea (n)6 2
Hypokalaemia (n)1 1 0
Sideroemia (n)9 0
Hyperglycaemia (n)1 2 0
Hyperuremia (n)2 0
Serum creatinine (n)9 0
Hepatic enzymes (n)6 0
Pain (n)1 8 2
Leucocytosis (n)1 50
Swelling (n)7 0
Grades according to WHO (Miller et al, 1981). IA¼intra-arterial.
Intra-arterial chemotherapy for oral cancer
AF Kova ´cs
1325
British Journal of Cancer (2004) 90(7), 1323–1328 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lPatients were followed up for a mean period of 36 months (SD
18.9; range 5–67 months). Overall and disease-free survival is
shown in Figure 1. For survival, there have been 43 (83%) censored
cases with a mean survival time of 55 months (95% confidence
interval of 49–62 months). The mean disease-free survival time
has been 49 months (95% confidence interval of 42–57 months).
At 3 years, overall survival was 82% and disease-free survival was
69%. Cumulative survival rates at 5 years were 77 and 59%,
respectively. Confidence intervals for survival are demonstrated in
Table 7. The survival expectancy for the whole population
according to the TPI was 63% at 3 years and 56% at 5 years
(Figure 1). The TPI estimator was at any point (1, 2, 3, 4, and 5
years) below the confidence range for survival (cf. Table 7).
DISCUSSION
The randomised studies on neoadjuvant IA chemotherapy,
conducted in the 80s of the last century, demonstrated a survival
benefit for oral cancer patients. However, oral cancer patients have
been a subset of larger study populations and, therefore,
calculation could not be estimated appropriately. Arcangeli et al
(1983) treated 72 head and neck cancer patients (stages 2–4) with
retrograde continuous IA local perfusion with methotrexate (3–
5mgday
 1, up to an overall dose of 90–120mg) before definitive
radiotherapy. Randomisation was against radiotherapy alone, and
the complete study population comprised 142 patients. The
subgroup of oral cancer patients had a 5-year survival of 54%,
which was significantly better than the comparison (27%). An
EORTC study (Richard et al, 1991) comprised 222 patients with
resectable floor of mouth and oropharyngeal carcinomas. In all,
112 patients were administered retrograde IA vincristin
(1mgday
 1) on 3 days and bleomycin (15mgday
 1) over 12 days
preoperatively. Only oropharyngeal cancer patients underwent
obligatory postoperative radiation, while radiation of floor of
mouth cancer patients was dependent on surgical margins and
lymph node state. Randomisation was against operation alone. The
subgroup of floor of mouth cancer patients had a survival
advantage, but oropharyngeal cancer patients did not. The third
randomised study (Szabo ´ et al, 1999) reported on 131 patients with
sublingual and lingual carcinomas (stages T2–4NXMX). The drugs
used were cisplatin (50mgday
 1) and epirubicin (60mgday
 1)
given alternating to 47 patients over a period of 12 days; the
approach was retrograde. Randomisation was against preoperative
radiation. The 5-year survival of the patients with IA chemother-
apy was not significantly better (38% vs 31%). The authors
nevertheless stressed the higher quality of life after IA chemother-
apy as compared to radiotherapy. Wound healing after surgery was
not disturbed, and chronic side effects of radiation like xerostomia
were lacking.
The report of Molinari et al (1999) made it unmistakably clear as
to why this treatment procedure was abandoned: the problems and
acute side effects of IA chemotherapy over a temporal approach
were too severe. Cannulation attempts (11%) have been not
successful; further complications have been dislocations and
occlusions of catheters (8%), local inflammations (15%), neuro-
logical complaints like temporary paralysis of the facial nerve
(4%), and discontinuations of perfusion (20%). Acute hematolo-
gical side effects with the drugs methotrexate, bleomycin,
adriamycin, and cisplatin have been observed in 2.8%.
It is obvious from the presented results that modern IA
chemotherapy over a transfemoral approach had less interven-
tional complications, had higher selectivity (no facial nerve
damage), and transported higher doses to the tumour area
(maximum dose 300mg cisplatin) than possible with earlier
methods due to systemic neutralisation.
The absolute survival results are better than reported elsewhere
with other IA regimens (von Scheel et al, 1996; Robbins et al,
Table 5 Neck dissections
Neck dissection Number
None 4
Ipsilateral MRND 8
Ipsilateral MRND, contralateral SHND 10
Ipsilateral SHND 5
Bilateral SHND 8
SNB 17
MRND¼type III modified radical ND; SHND¼suprahyoid ND; SNB¼sentinel
node biopsy.
Table 6 Distribution of pT and pN stages post-treatment
pN0 pN1 pN2a pN2b pN2c Total
pT0 11 1 1 0 0 13 (25%)
pT1 19 4 0 0 0 23 (44%)
pT2 5 1 0 0 1 7 (13%)
pT3 0 0 0 0 0 0
pT4 4 3 0 2 0 9 (18%)
Total 39 9 1 2 1 52 (100%)
‘Downstaging’ of primaries following IA chemotherapy; cf. Table 2. pT=pathological
tumor classification. pN=pathological nodal classification.
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Figure 1 Overall and disease-free survival of 52 patients treated with
neoadjuvant IA high-dose chemotherapy with cisplatin and radical surgery.
Comparison with expected survival according to a treatment-dependent
prognosis index TPI.
Table 7 Cumulative percentage of surviving subjects including 95%
confidence intervals
Time
(months)
Cumulative
survival (%)
Lower 95%
confidence
Upper 95%
confidence
12 90 81 98
24 85 75 95
36 82 70 93
48 77 63 91
60 77 63 91
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l2000b; Furutani et al, 2002), and papers on neoadjuvant usage of
IA chemotherapy failed to report long-term survival. The results of
the present paper prove the feasibility, safety, and effectivity of
neoadjuvant treatment with IA chemotherapy, and suggest that
survival of patients treated with neoadjuvant IA chemotherapy and
surgery was better than the survival expectancy calculated with the
help of a prognosis index. Considering the fact that IA
chemotherapy mainly has a local effect due to pharmacokinetics
(Tegeder et al, 2003), neoadjuvant usage in patients with the small
tumour stages 1 and 2 who had no clinical evidence of nodal
disease would be most logical.
Volling et al (1994, 1999) conducted a prospective randomised
trial on primary systemic chemotherapy with cisplatin and 5-
fluorouracil. This internationally less known trial could demon-
strate that especially patients with smaller resectable carcinomas of
the tonsils and the floor of mouth benefited from this neoadjuvant
treatment. The results of the present study point in the same
direction. The acute side effects of a systemic chemotherapy,
however, are much more frequent and higher. The extremely low
acute side effects of IA high-dose chemotherapy with systemic
neutralisation (Kova ´cs, 2003b) strongly recommend this method
when carried out over a transfemoral approach.
Although it could be demonstrated that complete and PRs of
oral carcinomas have a prognostic value after local chemotherapy
(Kova ´cs 2003a), it would be too early to conclude a change in
treatment for patients with local response. Therefore, surgical
radicality has been maintained. Repetitions of courses did not alter
the direction of initial response (Kova ´cs, 2003b), which is the
reason why one neoadjuvant course is adopted. In any way, it is
possible to investigate the necessity of postoperative treatment
modalities in patients with positive response, and to examine
genetical changes in tumours following chemotherapy.
It is generally accepted that specific therapeutic recommenda-
tions can be expressed only based on results of prospective
randomised studies. The statistical designs of such studies,
however, were often criticised. The main problems, as in the
studies mentioned above, were the high number of patients
required in both study arms to produce hard results, and
calculation of subsets in such heterogenous populations, which
has to be considered as inappropriate. In the light of this problem,
the consideration of a prognosis index, which is statistically more
than a historical control, may be indicated as a control for a pilot
study.
The TPI may be a better prognostic tool than TNM because it
additionally comprises tumour infiltration depth and the age
of the patients, which are accepted as highly relevant pro-
gnostic factors. It is based on a historical (retrospective and
prospective) observation, but the indices were calculated using
multivariate Cox’s regression. The author could demonstrate in a
monography on multimodality treatment of oral and orophar-
yngeal cancer that it is very difficult to surpass the survival
expectancy based on the TPI (Kova ´cs, 2003b). Therefore, the
results presented in this paper can cautiously be interpreted as a
survival benefit for the sample, and IA high-dose chemotherapy
with cisplatin with systemic neutralisation with sodium thiosul-
phate can surely be used in oral and oropharyngeal cancer patients
with great feasibility, safety, and effectivity. Low-grade toxicity
would especially suggest usage for stage 1–2 patients. Proof of a
survival benefit, however, requires a prospective randomised
study.
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